Kenta Takaura

Dr. Kenta Takaura

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2021 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
NTNobuharu Tamaki
Nobuharu Tamaki
MKMasayuki Kurosaki
Masayuki Kurosaki
YTYuka Takahashi
Yuka Takahashi
YIYoshie Itakura
Yoshie Itakura
KIKento Inada
Kento Inada
NINamiki Izumi
Namiki Izumi

9 October 2019 in Cancers
Verified
Journal Article
Open access
PDF file
WWWan Wang
Wan Wang
KTKaoru Tsuchiya
Kaoru Tsuchiya
MKMasayuki Kurosaki
Masayuki Kurosaki
YYYutaka Yasui
Yutaka Yasui
KIKento Inada
Kento Inada
NINamiki Izumi
Namiki Izumi
Background: We aimed to explore the relative dose intensity (RDI) and post-regorafenib treatments in regorafenib therapy. Methods: The medical records of 38 patients treated with regorafenib between July 2017 and June 2019 at our institution were collected. The RDI of regorafenib for the first month (1M-RDI) was calculated. Results: The overall survival (OS) and progression-free survival (PFS) were 12.4 and 3.7 months. The objective response rate and disease control rate were 13.2% and 71.1%. The median total dose of regorafenib in the first month was 2080 mg (240–3360 mg), and the median 1M-RDI was 61.9% (7.1–100%). Patients with 1M-RDI ≥ 50% showed significantly longer OS and PFS than patients with 1M-RDI < 50% (HR 0.19, 95% CI 0.08–0.48, p = 0.0004 and HR 0.2, 95% CI 0.08–0.52, p = 0.0008). A 1M-RDI ≥ 50% (HR 0.18, 95% CI 0.06–0.55, p = 0.002) and hand–foot skin reaction (HR 0.03, 95% CI 0.008–0.16, p < 0.0001) were independently associated with OS. Post-regorafenib therapies were performed in 19 (86.4%) of 22 patients who had stopped regorafenib due to disease progression. Conclusion: A 1M-RDI ≥ 50% is clinically significant. Post-regorafenib therapies are commonly performed in real-world practice.

21 July 2022 in Cancers
Verified
Journal Article
Open access
PDF file
HMHiroaki Matsumoto
Hiroaki Matsumoto
KTKaoru Tsuchiya
Kaoru Tsuchiya
HNHiroyuki Nakanishi
Hiroyuki Nakanishi
YHYuka Hayakawa
Yuka Hayakawa
YYYutaka Yasui
Yutaka Yasui
NINamiki Izumi
Namiki Izumi
Background: Sarcopenia is associated with overall survival in patients with hepatocellular carcinoma (HCC). However, it is not known whether muscle volume is associated with clinical outcomes during combination therapy with immune checkpoint inhibitors. We investigated the relationship between changes in muscle volume and treatment outcomes in patients treated with atezolizumab plus bevacizumab. Methods: Thirty-two patients with HCC who received atezolizumab plus bevacizumab as the first-line treatment between October 2020 and February 2022 were included. Skeletal muscle mass index (SMI) was calculated from the skeletal muscle area at the L3 level of the lumbar vertebrae. We compared pretreatment SMI and SMI at 6–14 weeks after administration. Results: Of the 32 patients, 18 had a decreased SMI, while 14 did not. Progression-free survival (PFS) was significantly longer in patients without SMI decrease than in patients with SMI decrease (8.5 vs. 5.8 months, p = 0.011). There were no significant differences in treatment-related adverse events between the patients with and without SMI. Presarcopenia at baseline was not significantly associated with PFS. Conclusions: Decreased SMI was significantly associated with PFS. Monitoring muscle volume during atezolizumab plus bevacizumab therapy is useful in clinical practice.

31 May 2021 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
SKShun Kaneko
Shun Kaneko
MKMasayuki Kurosaki
Masayuki Kurosaki
KIKento Inada
Kento Inada
SKSakura Kirino
Sakura Kirino
YHYuka Hayakawa
Yuka Hayakawa
NINamiki Izumi
Namiki Izumi

17 June 2023 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
SIShun Ishido
Shun Ishido
NTNobuharu Tamaki
Nobuharu Tamaki
YTYuka Takahashi
Yuka Takahashi
NUNaoki Uchihara
Naoki Uchihara
KSKeito Suzuki
Keito Suzuki
NINamiki Izumi
Namiki Izumi
Background: Patients with nonalcoholic fatty liver disease (NAFLD) are highly at risk for cardiovascular disease (CVD). However, the risk of developing CVD in patients with lean NAFLD is not yet fully understood. Therefore, this study aimed to compare the CVD incidence in Japanese patients with lean NAFLD and those with non-lean NAFLD. Methods: A total of 581 patients with NAFLD (219 with lean and 362 with non-lean NAFLD) were recruited. All patients underwent annual health checkups for at least 3 years, and CVD incidence was investigated during follow-up. The primary end-point was CVD incidence at 3 years. Results: The 3-year new CVD incidence rates in patients with lean and non-lean NAFLD were 2.3% and 3.9%, respectively, and there was no significant difference between two groups (p = 0.3). Multivariable analysis adjusted for age, sex, hypertension, diabetes, and lean NAFLD/non-lean NAFLD revealed that age (every 10 years) as an independent factor associated with CVD incidence with an odds ratio (OR) of 2.0 (95% confidence interval [CI]: 1.3–3.4), whereas lean NAFLD was not associated with CVD incidence (OR: 0.6; 95% CI: 0.2–1.9). Conclusions: CVD incidence was comparable between patients with lean NAFLD and those with non-lean NAFLD. Therefore, CVD prevention is needed even in patients with lean NAFLD.

17 March 2024 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
KSKeito Suzuki
Keito Suzuki
YYYutaka Yasui
Yutaka Yasui
KTKaoru Tsuchiya
Kaoru Tsuchiya
HMHiroaki Matsumoto
Hiroaki Matsumoto
YYYudai Yamazaki
Yudai Yamazaki
NINamiki Izumi
Namiki Izumi